Mangostenone Bioactive Compound from Garcinia mangostana L. as Antiviral Agent via Dual Inhibitors Against E6 HPV 16/18 Oncoprotein through Computational Simulation

Viol Dhea Kharisma, Priscilla Listiyani, Ahmad Affan Ali Murtadlo, Rizal Adistya Putra Pradana, A. N.M. Ansori, Alexander Patera Nugraha, Shilfiana Rahayu, Cici Tya Rahmawati, Angelina Andreevna Obukhova, Zurab Aslanovich Gasanov, Zalina Ahmedovna Dzaurova, Ramazan Magomedgadjievich Osmanov, Marina Nikolaevna Sizonenko, Maksim Rebezov, Vikash Jakhmola, Hery Purnobasuki, Dwi Kusuma Wahyuni

Research output: Contribution to journalArticlepeer-review


HPV is a DNA virus from Papillomaviridae about 170 types have been identified and most of these viruses can triger cervial cancer disease. Types of HPV that can trigger cervical cancer consist of HPV-16 and HPV-18 with around 70% of cases, HPV-6 and HPV-11 only trigger genital warts. Types of HPV-16 and HPV-18 are high risk in triggering cervical cancer. High risk HPV types have the ability to interfere with the performance of tumor suppressors in cells through oncoprotein activity. E6 is a crucial oncoprotein because it allows degradation of tumor suppressors in host cells, E6 can be a major target in antiviral drug design. Inhibition of the E6 domain by antiviral candidate compounds is an important part of preventing the formation of the E6-p53 complex and preventing cancer development. Garcinia mangostana L. (Mangosteen) is a traditional medicine for treating bacterial, viral, fungal infections, as an antioxidant, and for degenerative diseases. This study aims to explore the potential of mangostenone compounds from Garcinia mangostana L. as HPV antivirals through inhibition of the E6 oncoprotein on HPV-16 and HPV-18 through in silico study. In silico analysis methods such as drug likeness, antiviral probability, docking simulation, chemical interaction analysis, and molecular visualization were used in this study to reveal HPV antiviral candidates from Mangostenone derivatives. Mangostenone derivative compounds from Garcinia mangostana L. can be antiviral candidates for HPV through a dual inhibitory mechanism by Mangostenone A. These compounds have strong activity through more negative binding affinity values and weak bonds such as hydrogen and hydrophobic bonds compared to other mangostenone derivative compounds.

Original languageEnglish
Pages (from-to)5045-5050
Number of pages6
JournalResearch Journal of Pharmacy and Technology
Issue number11
Publication statusPublished - Nov 2023


  • Antiviral
  • Dual Inhibitors
  • Garcinia mangostana
  • HPV
  • Mangostenone


Dive into the research topics of 'Mangostenone Bioactive Compound from Garcinia mangostana L. as Antiviral Agent via Dual Inhibitors Against E6 HPV 16/18 Oncoprotein through Computational Simulation'. Together they form a unique fingerprint.

Cite this